Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 9:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 290 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Left Sided Heart Failure Clear all
Not listed Phase 1 Interventional

Study of Anginera in Adults With a Left Ventricular Assist Device (LVAD) as Bridge to Transplant

NCT00364598
View directory record Official record
Conditions
Heart Failure
Interventions
Anginera, a human tissue replacement therapy
Drug
Lead sponsor
Theregen, Inc.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
3
States / cities
New Haven, Connecticut • Baltimore, Maryland • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 30, 2009 · Synced Oct 21, 2026, 9:41 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Stem Cell Therapy in Patients With Severe Heart Failure & Undergoing Left Ventricular Assist Device Placement

NCT00869024
View directory record Official record
Conditions
Heart Failure
Interventions
Intramyocardial Delivery of Bone Marrow Derived Mononuclear Cells
Biological
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 13, 2020 · Synced Oct 21, 2026, 9:41 AM EDT
Terminated Not applicable Interventional

Use of 3-D Blood Pool Scintigraphy to Guide Left Ventricular Pacing Lead Placement in Patients Requiring Cardiac Resynchronization Therapy

NCT02669290
View directory record Official record
Conditions
Heart Failure, Left Ventricular Dysfunction, Cardiac Resynchronization Therapy
Interventions
Guided, Non-guided
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Oct 21, 2026, 9:41 AM EDT
Suspended Not applicable Interventional

Prospective Multi-Center Randomized Study for Evaluating the EVAHEART®2 Left Ventricular Assist System

NCT01187368
View directory record Official record
Conditions
Heart Failure
Interventions
EVAHEART Left Ventricular Assist System (LVAS), HeartMate 3
Device
Lead sponsor
Evaheart, Inc.
Industry
Eligibility
18 Years and older
Enrollment
399 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
12
States / cities
Gainesville, Florida • Tampa, Florida • Indianapolis, Indiana + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 21, 2026, 9:41 AM EDT
Terminated Not applicable Interventional

Evaluation of the Safety and Effectiveness of the DuraHeart™ LVAS

NCT00710567
View directory record Official record
Conditions
Heart Failure
Interventions
DuraHeart Left Ventricular Assist System (LVAS)
Device
Lead sponsor
Terumo Heart Inc.
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
25
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 20 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2019 · Synced Oct 21, 2026, 9:41 AM EDT
Completed Not applicable Interventional

Correlating QLV Interval to Left Ventricular (LV) Lead Position in Patients Receiving Cardiac Resynchronization Therapy.

NCT02166762
View directory record Official record
Conditions
Heart Failure, Cardiomyopathy, Cardiac Arrhythmia
Interventions
QLV interval measurement
Procedure
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jun 7, 2019 · Synced Oct 21, 2026, 9:41 AM EDT
Recruiting Phase 2 Interventional

A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy

NCT06979362
View directory record Official record
Conditions
Heart Failure
Interventions
CDR132L, Placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
40 Years to 84 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
29
States / cities
Birmingham, Alabama • Tucson, Arizona • Covina, California + 24 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 21, 2026, 9:41 AM EDT
Recruiting No phase listed Observational

Conduction System Vs Surgical Left Ventricular Epicardial Pacing For Coronary Sinus Lead Failure

NCT06342492
View directory record Official record
Conditions
Heart Failure With Reduced Ejection Fraction
Interventions
Coronary Sinus Lead Revision
Other
Lead sponsor
Kansas City Heart Rhythm Research Foundation
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 28, 2024 · Synced Oct 21, 2026, 9:41 AM EDT
Not listed Not applicable Interventional

Evaluation of the Jarvik 2000 Left Ventricular Assist System With Post-Auricular Connector--Destination Therapy Study

NCT01627821
View directory record Official record
Conditions
Heart Failure
Interventions
Jarvik 2000 VAS, HeartMate II
Device
Lead sponsor
Jarvik Heart, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 20, 2024 · Synced Oct 21, 2026, 9:41 AM EDT
Completed Phase 3 Interventional Results available

Inhaled Beta-adrenergic Agonists to Treat Pulmonary Vascular Disease in Heart Failure With Preserved EF (BEAT HFpEF): A Randomized Controlled Trial

NCT02885636
View directory record Official record
Conditions
Congestive Heart Failure, Heart Failure, Left-Sided, Left-Sided Heart Failure
Interventions
Albuterol, Saline placebo
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 22, 2019 · Synced Oct 21, 2026, 9:41 AM EDT
Recruiting No phase listed Observational

Hemodynamic Assessment of underLying myocyTe Function in Right Heart Failure

NCT06299436
View directory record Official record
Conditions
Heart Failure With Reduced Ejection Fraction, Pulmonary Hypertension, Right Heart Failure Due to Left Heart Failure
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 90 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Oct 21, 2026, 9:41 AM EDT
Completed Phase 1 Interventional

Safety Study of Chimeric Natriuretic Peptide(CD-NP) in Stable LVAD Patients

NCT01750905
View directory record Official record
Conditions
Left Ventricular Insufficiency
Interventions
CD-NP, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 30, 2016 · Synced Oct 21, 2026, 9:41 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

IC14 for Treatment of Acute Decompensated Heart Failure

NCT06556810
View directory record Official record
Conditions
Acute Decompensated Heart Failure
Interventions
Atibuclimab (IC14)
Drug
Lead sponsor
Implicit Bioscience
Industry
Eligibility
21 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Charlottesville, Virginia • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 21, 2026, 9:41 AM EDT
Completed No phase listed Observational

Neuron Specific Enolase in Ventricular Assist Device Recipients

NCT01643551
View directory record Official record
Conditions
Advanced Heart Failure, Left Ventrucular Assist Device
Interventions
Not listed
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 18, 2014 · Synced Oct 21, 2026, 9:41 AM EDT
Terminated Phase 2 Interventional Results available

Open-Label Study of Perhexiline in Patients With Hypertrophic Cardiomyopathy and Moderate to Severe Heart Failure

NCT02862600
View directory record Official record
Conditions
Cardiomyopathy, Hypertrophic, Cardiomyopathy, Hypertrophic, Familial
Interventions
Perhexiline, Use of bioanalytical assay to monitor plasma levels of perhexiline
Drug · Device
Lead sponsor
Heart Metabolics Limited
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
11
States / cities
Stanford, California • Indianapolis, Indiana • Baltimore, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2017 · Synced Oct 21, 2026, 9:41 AM EDT
Completed Not applicable Interventional

Optimizing Left Ventricular Lead To Improve Cardiac Output

NCT01399801
View directory record Official record
Conditions
Ischemic Congestive Cardiomyopathy, Dilated Cardiomyopathy, Congestive Heart Failure
Interventions
Doppler flow measurement, standard implantation of the LV lead
Procedure
Lead sponsor
Ann Marie Chikowski
Other
Eligibility
Not listed
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Wynnewood, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 30, 2022 · Synced Oct 21, 2026, 9:41 AM EDT
Completed No phase listed Observational Results available

Post Approval Registry of Corox OTW, Endocardial, Left Ventricular Steroid Lead, Bipolar

NCT00810264
View directory record Official record
Conditions
Congestive Heart Failure
Interventions
CRT Therapy - LV Lead Registry
Device
Lead sponsor
Biotronik, Inc.
Industry
Eligibility
18 Years and older
Enrollment
2,499 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
86
States / cities
Birmingham, Alabama • Glendale, Arizona • Mesa, Arizona + 83 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2019 · Synced Oct 21, 2026, 9:41 AM EDT
Completed No phase listed Observational

Cardiac Resynchronization Therapy (CRT) and Left Ventricular Assist Devices (LVAD) Therapy

NCT02083419
View directory record Official record
Conditions
Heart Failure
Interventions
LVAD CRT
Device
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 8, 2017 · Synced Oct 21, 2026, 9:41 AM EDT
Terminated Not applicable Interventional Results available

Survey of QRS Frequency at Various Left Ventricular Pacing Sites for Cardiac Resynchronization

NCT03253809
View directory record Official record
Conditions
Cardiomyopathies, Congestive Heart Failure
Interventions
Biotronik Vision Guidewire
Device
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 9, 2022 · Synced Oct 21, 2026, 9:41 AM EDT
Completed Phase 2Phase 3 Interventional

Device Evaluation of Contak Renewal 2and Easytrak 2 - DECREASE-HF

NCT00158951
View directory record Official record
Conditions
Congestive Heart Failure
Interventions
CONTAK RENEWAL 2/4/4HE CRT-D, EASYTRAK 2 Lead
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 25, 2007 · Synced Oct 21, 2026, 9:41 AM EDT
Completed Phase 2 Interventional Results available

COSMIC-HF - Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure

NCT01786512
View directory record Official record
Conditions
Modified Release Oral Formulation, Left Ventricular Systolic Dysfunction, Chronic Heart Failure, History of Chronic Heart Failure, Left Ventricular Ejection Fraction, Pharmacokinetics, Echocardiogram
Interventions
Omecamtiv Mecarbil Matrix F1 Formulation, Omecamtiv Mecarbil Matrix F2 Formulation, Placebo, Omecamtiv Mecarbil Swellable Core Technology F2
Drug
Lead sponsor
Cytokinetics
Industry
Eligibility
18 Years to 85 Years
Enrollment
544 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
38
States / cities
Mobile, Alabama • Costa Mesa, California • Fresno, California + 34 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2021 · Synced Oct 21, 2026, 9:41 AM EDT
Terminated No phase listed Observational

The Epidemiology of Bleeding and Clotting in Patients Undergoing Heart Transplantation, Coronary Artery Bypass Graft Surgery,or Implantation of Left Ventricular Assist Devices

NCT01481012
View directory record Official record
Conditions
Congestive Heart Failure
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
13
States / cities
Birmingham, Alabama • San Diego, California • Oak Lawn, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2011 · Synced Oct 21, 2026, 9:41 AM EDT
Completed Phase 4 Interventional Results available

Study on the Effects of Sacubitril/Valsartan on Physical Activity and Sleep in Heart Failure With Reduced Ejection Fraction Patients.

NCT02970669
View directory record Official record
Conditions
Heart Failure, Reduced Ejection Fraction
Interventions
sacubitril/valsartan (LCZ696), enalapril, matching placebo sacubitril/valsartan (LCZ696), matching placebo enalapril
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
23
States / cities
Fort Payne, Alabama • Beverly Hills, California • Stockton, California + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2021 · Synced Oct 21, 2026, 9:41 AM EDT
Completed No phase listed Observational

MOMENTUM 3 Pivotal Cohort Extended Follow-up PAS

NCT03982979
View directory record Official record
Conditions
Advanced Refractory Left Ventricular Heart Failure
Interventions
HM3 LVAS
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
Not listed
Enrollment
295 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Burlington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 24, 2022 · Synced Oct 21, 2026, 9:41 AM EDT